dipyridamole has been researched along with Colorectal Neoplasms in 15 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Aspirin use after diagnosis of colorectal cancer was associated with significantly lower mortality rates and this effect remained significant after adjusting for potential confounders." | 7.85 | The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer. ( Bastiaannet, E; Frouws, MA; Lemmens, VE; Liefers, GJ; Portielje, JEA; Rademaker, E; Van de Velde, CJH; van Herk-Sukel, MPP, 2017) |
| "Twenty-six patients with advanced colorectal cancer were treated with a combination based on multimodal biochemical modulation of 5-fluorouracil by means of high dose folinic acid, low-dose alpha-2b interferon and dipyridamole." | 7.68 | Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study. ( Arcangeli, G; Bonera, F; Braga, M; Marini, G; Marpicati, P; Meriggi, F; Montini, E; Ragni, F; Simoncini, E; Zaniboni, A, 1991) |
| "In 28 patients with advanced colorectal cancer, in progression under FA-5FU, we continued treatment with FA-5FU plus DIP." | 6.67 | Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with allopurinol, folinic acid and dipyridamol. ( Antonopoulos, A; Bacoyannis, C; Beldecos, D; Karvounis, N; Kosmidis, P; Mylonacis, N; Tsavaris, N; Valilis, P; Zamanis, N; Zinelis, A, 1990) |
| "Aspirin is a well-known non-steroid anti-inflammatory drug." | 5.91 | Dipyridamole enhances the anti-cancer ability of aspirin against colorectal cancer by inducing apoptosis in an unfolded protein response-dependent manner. ( Hu, LP; Huang, S; Huang, WQ; Ji, J; Jiang, SH; Li, DX; Li, J; Sundquist, J; Sundquist, K; Xing, X; Xu, CJ; Yao, LL; Zhang, NQ; Zhang, XL; Zhang, ZG, 2023) |
| "Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months." | 5.27 | [Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988) |
| "A joint multicenter comparative study of carmofur (HCFU) alone or HCFU+dipyridamole (DP) concurrent administration was conducted by the Kinki Colorectal Cancer Chemotherapy Society." | 5.07 | [Some problems of TS measurement after administration of fluoropyrimidines in colorectal cancer. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma]. ( Fukuda, I; Hioki, K; Imaoka, S; Kameyama, M; Kikkawa, N; Mori, T; Nakamori, S; Oshima, A; Utsunomiya, J; Yasutomi, M, 1993) |
| "For nearly four decades, 5-fluorouracil (5-FU) has been the mainstay of treatment for colorectal cancer." | 4.80 | Where do we stand with 5-fluorouracil? ( Büchele, T; Dempke, W; Grothey, A; Schmoll, HJ, 1999) |
| "Aspirin use after diagnosis of colorectal cancer was associated with significantly lower mortality rates and this effect remained significant after adjusting for potential confounders." | 3.85 | The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer. ( Bastiaannet, E; Frouws, MA; Lemmens, VE; Liefers, GJ; Portielje, JEA; Rademaker, E; Van de Velde, CJH; van Herk-Sukel, MPP, 2017) |
| "Twenty-six patients with advanced colorectal cancer were treated with a combination based on multimodal biochemical modulation of 5-fluorouracil by means of high dose folinic acid, low-dose alpha-2b interferon and dipyridamole." | 3.68 | Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study. ( Arcangeli, G; Bonera, F; Braga, M; Marini, G; Marpicati, P; Meriggi, F; Montini, E; Ragni, F; Simoncini, E; Zaniboni, A, 1991) |
| "In 28 patients with advanced colorectal cancer, in progression under FA-5FU, we continued treatment with FA-5FU plus DIP." | 2.67 | Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with allopurinol, folinic acid and dipyridamol. ( Antonopoulos, A; Bacoyannis, C; Beldecos, D; Karvounis, N; Kosmidis, P; Mylonacis, N; Tsavaris, N; Valilis, P; Zamanis, N; Zinelis, A, 1990) |
| "Dipyridamole (DP) has previously been studied both in vitro and in vivo in combination with various anti-metabolites, including methotrexate and 5-fluorouracil (5FU)." | 2.66 | Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients. ( Alberts, DS; Buzaid, AC; Einspahr, J; Garewal, HS; Mosley, K; Peng, YM; Spears, CP; Tutsch, K, 1989) |
| "Aspirin is a well-known non-steroid anti-inflammatory drug." | 1.91 | Dipyridamole enhances the anti-cancer ability of aspirin against colorectal cancer by inducing apoptosis in an unfolded protein response-dependent manner. ( Hu, LP; Huang, S; Huang, WQ; Ji, J; Jiang, SH; Li, DX; Li, J; Sundquist, J; Sundquist, K; Xing, X; Xu, CJ; Yao, LL; Zhang, NQ; Zhang, XL; Zhang, ZG, 2023) |
| " Preoperative regimens of HCFU 240 mg/m2/day, given by 14-day oral dosage or HCFU 240 mg/m2/day and DP (Dipyridamole) 300 mg/body/day, both 14-day oral dosage were used." | 1.29 | [TS inhibition rate and flow cytometric analysis of DNA content in preoperative chemotherapy with biochemical modulator]. ( Sakuyama, T; Takahashi, N, 1994) |
| "Mitomycin C was given to 9 patients as a third-line regimen with resulting 5 NC for 2-4 months." | 1.27 | [Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C]. ( Farroukh, R; Gerlach, D; Hoffmann, W; Kress, M; Migeod, F; Seeber, S, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 9 (60.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 1 (6.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, S | 1 |
| Zhang, NQ | 1 |
| Xu, CJ | 1 |
| Huang, WQ | 1 |
| Li, DX | 1 |
| Li, J | 1 |
| Yao, LL | 1 |
| Sundquist, K | 1 |
| Sundquist, J | 1 |
| Jiang, SH | 1 |
| Xing, X | 1 |
| Hu, LP | 1 |
| Zhang, ZG | 1 |
| Ji, J | 1 |
| Zhang, XL | 1 |
| Frouws, MA | 1 |
| Rademaker, E | 1 |
| Bastiaannet, E | 1 |
| van Herk-Sukel, MPP | 1 |
| Lemmens, VE | 1 |
| Van de Velde, CJH | 1 |
| Portielje, JEA | 1 |
| Liefers, GJ | 1 |
| Köhne, CH | 2 |
| Hiddemann, W | 1 |
| Schüller, J | 1 |
| Weiss, J | 1 |
| Lohrmann, HP | 1 |
| Schmitz-Hübner, U | 1 |
| Bodenstein, H | 1 |
| Schöber, C | 1 |
| Wilke, H | 2 |
| Grem, J | 1 |
| Sakuyama, T | 1 |
| Takahashi, N | 1 |
| Kameyama, M | 2 |
| Nakamori, S | 1 |
| Imaoka, S | 1 |
| Utsunomiya, J | 2 |
| Oshima, A | 2 |
| Kikkawa, N | 2 |
| Hioki, K | 2 |
| Fukuda, I | 2 |
| Mori, T | 2 |
| Yasutomi, M | 2 |
| Kanno, H | 1 |
| Yoden, Y | 1 |
| Ohashi, S | 1 |
| Iwanaga, T | 1 |
| Schöffski, P | 1 |
| Schmoll, HJ | 2 |
| Büchele, T | 1 |
| Grothey, A | 1 |
| Dempke, W | 1 |
| Lehman, NL | 1 |
| Danenberg, PV | 1 |
| Zaniboni, A | 1 |
| Marpicati, P | 1 |
| Simoncini, E | 1 |
| Montini, E | 1 |
| Meriggi, F | 1 |
| Arcangeli, G | 1 |
| Bonera, F | 1 |
| Braga, M | 1 |
| Ragni, F | 1 |
| Marini, G | 1 |
| Kosmidis, P | 2 |
| Kozatsani-Halvidi, D | 1 |
| Tsaroucha, E | 1 |
| Tsavaris, N | 2 |
| Zinelis, A | 1 |
| Karvounis, N | 1 |
| Beldecos, D | 1 |
| Mylonacis, N | 1 |
| Zamanis, N | 1 |
| Bacoyannis, C | 1 |
| Valilis, P | 1 |
| Antonopoulos, A | 1 |
| Buzaid, AC | 1 |
| Alberts, DS | 1 |
| Einspahr, J | 1 |
| Mosley, K | 1 |
| Peng, YM | 1 |
| Tutsch, K | 1 |
| Spears, CP | 1 |
| Garewal, HS | 1 |
| Wyngaarden, JB | 1 |
| Migeod, F | 1 |
| Gerlach, D | 1 |
| Kress, M | 1 |
| Hoffmann, W | 1 |
| Farroukh, R | 1 |
| Seeber, S | 1 |
2 reviews available for dipyridamole and Colorectal Neoplasms
| Article | Year |
|---|---|
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clin | 1996 |
Where do we stand with 5-fluorouracil?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chro | 1999 |
5 trials available for dipyridamole and Colorectal Neoplasms
| Article | Year |
|---|---|
Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopla | 1995 |
[Some problems of TS measurement after administration of fluoropyrimidines in colorectal cancer. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Dipyridamole; Female; Fluorouracil; Humans | 1993 |
[Comparative study of the combined effect of HCFU and dipyridamole (DP) in colorectal carcinoma--TS inhibition rate. Kinki Cooperative Study Group of Chemotherapy for Colorectal Carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Dru | 1996 |
Multimodal biochemical modulation of 5-fluorouracil activity in advanced colorectal cancer with allopurinol, folinic acid and dipyridamol.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Ne | 1990 |
Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients.
Topics: Bone Marrow; Cell Line; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Colorectal N | 1989 |
8 other studies available for dipyridamole and Colorectal Neoplasms
| Article | Year |
|---|---|
Dipyridamole enhances the anti-cancer ability of aspirin against colorectal cancer by inducing apoptosis in an unfolded protein response-dependent manner.
Topics: Animals; Anti-Inflammatory Agents; Apoptosis; Aspirin; Colorectal Neoplasms; Dipyridamole; Humans; M | 2023 |
The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Colorectal Neoplasms; Dipyridamole; Drug Thera | 2017 |
[TS inhibition rate and flow cytometric analysis of DNA content in preoperative chemotherapy with biochemical modulator].
Topics: Administration, Oral; Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms; Dipyridamole; DNA, | 1994 |
Modulation of RTX cytotoxicity by thymidine and dipyridamole in vitro: implications for chemotherapy.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dipyridamole; Dose-Response Relationship, Dru | 2000 |
Fluorouracil, high-dose folinic acid, low-dose alpha-2b interferon and dipyridamole in the treatment of advanced colorectal cancer. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Fem | 1991 |
Therapeutic doses of dipyridamole failed to potentiate 5-fluorouracil tumor activity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Female; Fluorour | 1991 |
From the National Institutes of Health.
Topics: Acquired Immunodeficiency Syndrome; Carcinoma; Colorectal Neoplasms; Dipyridamole; Humans; Interfero | 1989 |
[Sequential treatment of progressive metastatic colorectal cancer with 5-fluorouracil/folinic acid, dipyramidole and mitomycin C].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dipyridamole; Dos | 1988 |